Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 8/20 | 0.69 |
| ▸ | EGFR | P00533 | 4/20 | 0.65 |
| ▸ | ZAP70 | P43403 | 6/20 | 0.59 |
| ▸ | ULK1 | O75385 | 1/20 | 0.59 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.57 |
| ▸ | INSR | P06213 | 1/20 | 0.55 |
| ▸ | IGF1R | P08069 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL382124 | 0.92 | ALK (0.81) | ALKEGFRZAP70ULK1INSR | |
| SCHEMBL1912072 | 0.92 | ULK1 (0.71) | ALKEGFRZAP70ULK1IGF1R | |
| SCHEMBL1912069 | 0.92 | ALK (0.58) | ALKEGFRZAP70ULK1IGF1R | |
| SCHEMBL1911961 | 0.91 | EGFR (0.65) | ALKEGFRZAP70ULK1MAPK3 | |
| SCHEMBL12781794 | 0.91 | ZAP70 (0.72) | ALKEGFRZAP70ULK1INSR | |
| SCHEMBL1912070 | 0.91 | ZAP70 (0.59) | ALKEGFRZAP70ULK1INSR | |
| SCHEMBL12729207 | 0.89 | ALK (0.75) | ALKEGFRZAP70MAPK3INSR | |
| SCHEMBL12892825 | 0.87 | ZAP70 (0.64) | ALKEGFRZAP70ULK1INSR | |
| SCHEMBL12892823 | 0.87 | ZAP70 (0.64) | ALKEGFRZAP70ULK1INSR | |
| SCHEMBL12892761 | 0.87 | EGFR (0.68) | ALKEGFRZAP70ULK1MAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660458-B1 | 2, 4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NOVARTIS AG (CH) | 2012-01-25 | — | — | EP | disclosed |
| EP-2287156-A1 | 2,4-Di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | Novartis AG (CH) | 2011-02-23 | — | — | EP | disclosed |